Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S SCHWARTZBERG

Showing results (71-80 of 222) with videos related to

Pageof 23
Sort By:
Cancer Medicine|October 19, 2022
Mobile application to support oncology patients during treatment on patient outcomes: Evidence from a randomized controlled trialIlana Graetz, Xin Hu, Andrea N Curry, et al.
Journal of Cancer Survivorship : Research and Practice|March 2, 2018
Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trialIlana Graetz, Caitlin N McKillop, Edward Stepanski, et al.
Health and Quality of Life Outcomes|June 22, 2011
Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patientsMark S Walker, Murad Hasan, Yeun Mi Yim, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 15, 2018
Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilarLee S Schwartzberg, Lincy S Lal, Sanjeev Balu, et al.
The Oncologist|November 25, 2004
A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancerLee S Schwartzberg, Lorrin K Yee, Frank M Senecal, et al.
The Oncologist|February 17, 2010
Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancerLee S Schwartzberg, Lee S Schwarzberg, Sandra X Franco, et al.
Future Oncology (London, England)|July 6, 2021
Real-world treatment patterns and effectiveness outcomes in patients with early-stage triple-negative breast cancerAmin Haiderali, Whitney C Rhodes, Santosh Gautam, et al.
Future Oncology (London, England)|July 13, 2021
Healthcare resource utilization and cost among patients treated for early-stage triple-negative breast cancerAmin Haiderali, Whitney C Rhodes, Santosh Gautam, et al.
Cancer Chemotherapy and Pharmacology|January 23, 2014
Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumorsClinton F Stewart, Michael Tagen, Lee S Schwartzberg, et al.
Progress in Clinical and Biological Research|January 1, 1990
LAK cell therapy--clinical studies and future potentialG D Marshall, L S Schwartzberg, K W Tauer, et al.
Pageof 23

Showing results (71-80 of 222) with videos related to

Sort By:
Pageof 23
Cancer Medicine|October 19, 2022
Mobile application to support oncology patients during treatment on patient outcomes: Evidence from a randomized controlled trialIlana Graetz, Xin Hu, Andrea N Curry, et al.
Journal of Cancer Survivorship : Research and Practice|March 2, 2018
Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trialIlana Graetz, Caitlin N McKillop, Edward Stepanski, et al.
Health and Quality of Life Outcomes|June 22, 2011
Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patientsMark S Walker, Murad Hasan, Yeun Mi Yim, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 15, 2018
Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilarLee S Schwartzberg, Lincy S Lal, Sanjeev Balu, et al.
The Oncologist|November 25, 2004
A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancerLee S Schwartzberg, Lorrin K Yee, Frank M Senecal, et al.
The Oncologist|February 17, 2010
Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancerLee S Schwartzberg, Lee S Schwarzberg, Sandra X Franco, et al.
Future Oncology (London, England)|July 6, 2021
Real-world treatment patterns and effectiveness outcomes in patients with early-stage triple-negative breast cancerAmin Haiderali, Whitney C Rhodes, Santosh Gautam, et al.
Future Oncology (London, England)|July 13, 2021
Healthcare resource utilization and cost among patients treated for early-stage triple-negative breast cancerAmin Haiderali, Whitney C Rhodes, Santosh Gautam, et al.
Cancer Chemotherapy and Pharmacology|January 23, 2014
Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumorsClinton F Stewart, Michael Tagen, Lee S Schwartzberg, et al.
Progress in Clinical and Biological Research|January 1, 1990
LAK cell therapy--clinical studies and future potentialG D Marshall, L S Schwartzberg, K W Tauer, et al.
Pageof 23